Understanding pain in women with polyendocrine metabolic ovarian syndrome: health risks and treatment effectiveness.

20.67% of women with PMOS experience pain, with the highest prevalence among Black or African American (32.70%) and White (30.78%) populations.

• Why it matters: Pain in women with PMOS remains underexplored, despite its significant impact on health outcomes and potential racial disparities, highlighting a critical gap in understanding and management.
• What they did: Cherlin et al. conducted a retrospective analysis of electronic health records from over 100 million women across 120 healthcare organizations, assessing pain prevalence, health risks, and medication effects in women with PMOS.
• The result: Women with PMOS and pain have increased risks for conditions like ovarian cysts and mental health issues, and treatment with PMOS-related medications reduced pain, emphasizing the importance of routine pain assessment and personalized care strategies.